Method of in-vitro diagnosis of an increased risk for contrast-induced nephropathy (CIN) in a patient even before the patient is subjected to coronary angiography or any examination requiring the administration of a contrast medium. The disclosure comprises an immunological determination of the kynurenine concentration in serum and informs the physician of the risks of a MARE (major adverse renal event) or MACE (major cardiovascular event).